Freeline Therapeutics (FRLN)
NASDAQ: FRLN
· Real-Time Price · USD
6.49
0.01 (0.15%)
At close: Feb 16, 2024, 8:37 PM
0.15% (1D)
| Bid | n/a |
| Market Cap | 28.28M |
| Revenue (ttm) | 622K |
| Net Income (ttm) | -49.93M |
| EPS (ttm) | -11.4 |
| PE Ratio (ttm) | -0.5692982456140351 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 5,349 |
| Avg. Volume (20D) | 28,144 |
| Open | 6.49 |
| Previous Close | 6.48 |
| Day's Range | 6.48 - 6.49 |
| 52-Week Range | 2.11 - 8.74 |
| Beta | 0.66 |
About FRLN
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 2020
Employees 152
Stock Exchange NASDAQ
Ticker Symbol FRLN
Website https://www.freeline.life